Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 6/20 | 0.40 |
| ▸ | CYP3A5 | P20815 | 4/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.40 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | MC4R | P32245 | 1/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | HTR7 | P34969 | 1/20 | 0.35 |
| ▸ | HTR6 | P50406 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | MET | P08581 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3562449 | 0.99 | CYP3A4 (0.39) | CYP3A4CYP3A5OPRD1DOT1LSMN1; SMN2 | |
| SCHEMBL2138820 | 0.81 | CYP3A4 (0.55) | CYP3A4CYP3A5KDM4EALDH1A1 | |
| SCHEMBL2909512 | 0.80 | CYP3A4 (0.40) | CYP3A4CYP3A5SMN1; SMN2LMNAHTR7 | |
| SCHEMBL4711968 | 0.78 | CYP3A4 (0.42) | CYP3A4CYP3A5SMN1; SMN2LMNANPSR1 | |
| SCHEMBL2906643 | 0.78 | CACNA2D1 (0.39) | CYP3A4CYP3A5LMNAMAPTTSHR | |
| SCHEMBL1990504 | 0.77 | FFAR2 (0.39) | SMN1; SMN2LMNAMAPTTSHR | |
| Drinabant SCHEMBL684143 | 0.76 | CYP3A4 (0.36) | CYP3A4CYP3A5OPRD1OPRM1ALDH1A1 | |
| SCHEMBL2906523 | 0.76 | HSD17B1 (0.40) | CYP3A4CYP3A5OPRD1LMNAOPRM1 | |
| SCHEMBL2905664 | 0.76 | CYP3A4 (0.54) | CYP3A4CYP3A5 | |
| SCHEMBL2906358 | 0.76 | CYP3A4 (0.54) | CYP3A4CYP3A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1263722-B1 | PHARMACEUTICAL COMPOSITIONS CONTAINING AZETIDINE DERIVATIVES, NOVEL AZETIDINE DERIVATIVES AND PREPARATION THEREOF | AVENTIS PHARMA SA (FR) | 2010-08-25 | — | — | EP | claimed |
| US-7687493-B2 | Product, method and intermediates for the preparation of azetidine derivatives | AVENTIS PHARMA SA (FR) | 2010-03-30 | — | — | US | claimed |
| US-20070270463-A1 | NOVEL PRODUCT, METHOD AND INTERMEDIATES FOR THE PREPARATION OF AZETIDINE DERIVATIVES | SANOFI-AVENTIS (FR) | 2007-11-22 | — | — | US | claimed |
| EP-1805167-A2 | NOVEL PRODUCT, METHOD AND INTERMEDIATES FOR THE PREPARATION OF AZETIDINE DERIVATIVES | Aventis Pharma S.A. (FR) | 2007-07-11 | — | — | EP | claimed |
| WO-2006040465-A2 | NOVEL PRODUCT, METHOD AND INTERMEDIATES FOR THE PREPARATION OF AZETIDINE DERIVATIVES | AVENTIS PHARMA S.A. (FR) | 2006-04-20 | — | — | WO | claimed |
| EP-1328269-B1 | ASSOCIATION OF A CB1 RECEPTOR ANTAGONIST AND SIBUTRAMIN FOR TREATING OBESITY | AVENTIS PHARMA SA (FR) | 2004-05-26 | — | — | EP | claimed |
| JP-2003525270-A | — | — | 2003-08-26 | — | — | JP | claimed |
| EP-1328269-A2 | ASSOCIATION OF THE CB1 RECEPTOR ANTAGONIST AND A SIBUTRAMIN FOR TREATING OBESITY | Aventis Pharma S.A. (FR) | 2003-07-23 | — | — | EP | claimed |
| CN-1418192-A | Pharmaceutical compositions containing azetidine derivatives novel azetidine derivatives and preparation thereof | AVENTIS PHARMA SA (FR) | 2003-05-14 | — | — | CN | claimed |
| EP-1263722-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING AZETIDINE DERIVATIVES, NOVEL AZETIDINE DERIVATIVES AND PREPARATION THEREOF | Aventis Pharma S.A. (FR) | 2002-12-11 | — | — | EP | claimed |
| US-20020091114-A1 | Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity | AVENTIS PHARMA S.A. (FR) | 2002-07-11 | — | — | US | claimed |
| WO-2002028346-A2 | ASSOCIATION OF THE CB1 RECEPTOR ANTAGONIST AND SIBUTRAMIN, FOR TREATING OBESITY | AVENTIS PHARMA S.A. (FR) | 2002-04-11 | — | — | WO | claimed |
| US-6355631-B1 | TREATMENT OF PSYCHOSIS AND SCHIZOPHRENIA | AVENTIS PHARMA S.A. (FR) | 2002-03-12 | — | — | US | claimed |
| WO-2001064634-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING AZETIDINE DERIVATIVES, NOVEL AZETIDINE DERIVATIVES AND PREPARATION THEREOF | AVENTIS PHARMA S.A. (FR) | 2001-09-07 | — | — | WO | claimed |
| US-20110053903-A1 | PHARMACEUTICAL COMPOSITIONS BASED ON AZETIDINE DERIVATIVES | AVENTIS PHARMA SA (FR) | 2011-03-03 | — | — | US | disclosed |
| EP-1263722-B1 | PHARMACEUTICAL COMPOSITIONS CONTAINING AZETIDINE DERIVATIVES, NOVEL AZETIDINE DERIVATIVES AND PREPARATION THEREOF | AVENTIS PHARMA SA (FR) | 2010-08-25 | — | — | EP | disclosed |
| US-7687493-B2 | Product, method and intermediates for the preparation of azetidine derivatives | AVENTIS PHARMA SA (FR) | 2010-03-30 | — | — | US | disclosed |
| WO-2002028346-A2 | ASSOCIATION OF THE CB1 RECEPTOR ANTAGONIST AND SIBUTRAMIN, FOR TREATING OBESITY | AVENTIS PHARMA S.A. (FR) | 2002-04-11 | — | — | WO | disclosed |
| US-6355631-B1 | TREATMENT OF PSYCHOSIS AND SCHIZOPHRENIA | AVENTIS PHARMA S.A. (FR) | 2002-03-12 | — | — | US | disclosed |
| WO-2001064634-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING AZETIDINE DERIVATIVES, NOVEL AZETIDINE DERIVATIVES AND PREPARATION THEREOF | AVENTIS PHARMA S.A. (FR) | 2001-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270463-A1 | NOVEL PRODUCT, METHOD AND INTERMEDIATES FOR THE PREPARATION OF AZETIDINE DERIVATIVES | QDPR, AZI2, NISCH | CYP3A4 85/4885CYP3A5 154/4885OPRD1 525/4885 |
| US-20110053903-A1 | PHARMACEUTICAL COMPOSITIONS BASED ON AZETIDINE DERIVATIVES | ABCG2, CYP2C19, ABCC9 | CYP3A4 364/4885CYP3A5 119/4885OPRD1 843/4885 |
| US-20020091114-A1 | Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity | CNR2, CNR1, GPR119 | CYP3A4 1369/4885CYP3A5 720/4885OPRD1 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.